Cognitive Dysfunction, Depression and Anxiety in a Cohort of Systemic Lupus Erythematosus Patients

ANDREEA LILI BARBULESCU1*, RALUCA-ELENA SANDU2, MIHAI VIRGIL BOLDEANU3, FLORENTIN ANANU VREJ4, RADU ALEXANDRU MIHALIOVICI5, LIDIA BOLDEANU5, HORATIU VALERIU POPOVICI1, RAZVAN ADRIAN IONESCU4, BOGDAN CATALIN1, ANDREEA CRISTINA STOIAN16, OANA ANDREEA FLORESCU17, CARMEN VALERIA ALBU18

1University of Medicine and Pharmacy of Craiova, Pharmacology Department, 2 Petru Rares Str., 200349 Craiova, Romania
2University of Medicine and Pharmacy of Craiova, Biochemistry Department, 2 Petru Rares Str., 200349 Craiova, Romania
3University of Medicine and Pharmacy of Craiova, Immunology Department, 2 Petru Rares Str., 200349 Craiova, Romania
4University of Medicine and Pharmacy of Craiova, Rheumatology Department, 2 Petru Rares Str., 200349 Craiova, Romania
5University of Medicine and Pharmacy of Craiova, Cardiology Department, 2 Petru Rares Str., 200349 Craiova, Romania
6University of Medicine and Pharmacy of Craiova, Microbiology Department, 2 Petru Rares Str., 200349 Craiova, Romania
7University of Medicine, Pharmacy, Science and Technology of Targu Mures, Department of Rheumatology, BFK and Medical Rehabilitation, 38 Gheorghe Marinescu Str., 540139 Targu Mures, Romania
8Carol Davila University of Medicine and Pharmacy Bucharest, 3d Internal Medicine Department, 37 Dionisie Lupu Str., 020021 Bucharest, Romania
9University of Medicine and Pharmacy of Craiova, Physiology Department, 2 Petru Rares Str., 200349 Craiova, Romania
10University of Medicine and Pharmacy of Craiova, Infectious disease Department, 2 Petru Rares Str., 200349 Craiova, Romania
11University of Medicine and Pharmacy of Craiova, PhD student, Radiology and Imaging Department, 2 Petru Rares Str., 200349 Craiova, Romania
12University of Medicine and Pharmacy of Craiova, Neurology Department, 2 Petru Rares Str., 200349 Craiova, Romania
13University of Medicine and Pharmacy of Craiova, PhD student, Radiology and Imaging Department, 2 Petru Rares Str., 200349 Craiova, Romania
14University of Medicine and Pharmacy of Craiova, Radiology Department, 2 Petru Rares Str., 200349 Craiova, Romania
15University of Medicine and Pharmacy of Craiova, Department of Radiology, 2 Petru Rares Str., 200349 Craiova, Romania
16University of Medicine and Pharmacy of Craiova, Radiology Department, 2 Petru Rares Str., 200349 Craiova, Romania
17University of Medicine and Pharmacy of Craiova, Neurology Department, 2 Petru Rares Str., 200349 Craiova, Romania
18University of Medicine and Pharmacy of Craiova, PhD student, Radiology and Imaging Department, 2 Petru Rares Str., 200349 Craiova, Romania

SLE is the prototype of connective tissue diseases that can present the complete spectrum of neurologic and psychiatric disorders, cognitive dysfunction, depression and anxiety being more prevalent compared to general population, with an input on patients' prognosis and quality of life. In this study we aimed to determine the presence of cognitive dysfunction, anxiety and depression in a cohort of SLE patients, and their relationship to disease activity and quality of life. We determined the presence of these neuropsychiatric manifestations in significant percentages, directly correlated to disease activity and with an impact of quality of life. Our results lead to its extension, with multicentric contribution, and underline the necessity and benefit of a careful and periodical neuropsychiatric examination, in order to recognize the clinical patterns in early stages, apply the proper therapeutic measures, quantify the future damage and improve the outcome of these patients.

Keywords: systemic lupus erythematosus, cognitive dysfunction, depression, anxiety, disease activity, life quality.

Systemic lupus erythematosus (SLE) is a complex connective tissue disease, characterized by multisystem involvement, and although any of the autoimmune, inflammatory disease can determine neuroinflammation, it represents their prototype, being the typical pathology that can produce neurological and psychiatric disorders [1-11]. Compared to other clinical patterns, their primary etiologic diagnosis is not so very easily to be established despite the availability of many imagistic techniques [2, 12-15]. The clinical spectrum of neuropsychiatric SLE is complex, includes 19 entities, focal or diffuse, with variable prevalences [16], and from those, cognitive dysfunction, depression and anxiety are relatively often observed, with an important input on patients prognosis and life quality. As noticed in any autoimmune disease, imaging methods, along with immunologic studies, enable an early diagnosis and individualized therapeutic measures [1, 17-25].

Experimental part

The aim of the study was to determine the presence of cognitive dysfunction, anxiety and depression in a cohort of SLE patients, and their relationship to disease activity and quality of life.

Material and methods

We performed a longitudinal, prospective study, which included a cohort of 22 patients, diagnosed with SLE, according to the ACR/SCLICC 2012 revised criteria [25], in the Department of Rheumatology, Emergency County Hospital of Craiova, Romania. The control group included 18 sex and age-matched subjects, without acute or chronic inflammatory diseases, history of connective tissue, other autoimmune diseases or neuropsychiatric pathology. The study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the University of Medicine and Pharmacy of Craiova. All patients provided their written informed consent, after receiving a standard form which mentioned that the results would be used for research purposes.

Patients evaluation included anamnestic data, clinical examination, laboratory tests and imagistic methods. Disease activity was assessed using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [26], that ranges from 0 to 105, and defines remission when is 0, low activity 1-5, moderate activity 6-11, high disease activity 11-19 and very high disease activity over 20; a persistent SLEDAI over 3 defines a chronic activity [27].

Cognitive dysfunction, depression and anxiety were evaluated by the same examiner, blinded by clinical and laboratory date. In order to assess the presence of cognitive dysfunction we used scale Montreal Cognitive Assessment scale (MoCA), that is relatively easy to be performed and evaluates five cognitive domains (attention, executive function, memory, visuospatial function and language). The
MoCA assesses several cognitive domains: visuospatial functions (copy of cube, 1 point); clock drawing (3 points); naming (3 pictures, 3 points); memory learning of 5 words - delayed recall (5 words, 5 points); attention, concentration, and working memory are evaluated using a sustained attention task (target detection using tapping, 1 point), a serial subtraction task (3 points), and digits forward and backward (1 point each); language repetition (2 sentences, 2 points); abstract thinking similarities (2 points); abstract thinking similarities (2 points); orientation (6 tasks, 6 points). An MoCA score of less than 26 points was defined as cognitive dysfunction [28]. Depression was evaluated using HAM-D (Hamilton Depression Scale); a score under 7 points defines normal, 8-13 mild depression, 14-18 moderate, 19-22 severe and over 23 very severe depression [29]. We assessed anxiety by using HAM-A (Hamilton Anxiety Rating Scale), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate and 25-30 moderate to severe [30].

Life quality was estimated using short form survey (SF-36) and Systemic lupus erythematosus-specific Quality of Life questionnaire (SLEQol). SF-36 form is an indicator of overall health status, has eight scaled scores (energy, physical functioning, general health, pain, role limitation due to emotional problems, role limitation due to physical problems, emotional well-being and social functioning), each of them ranging from 0 to 100; lower scores correspond to high disability, high scores to less disability [31, 32]. SLEQol quantifies six domains, including physical functioning (6 items), activities (9 items), symptoms (8 items), treatment (4 items), mood (4 items) and self-image (9 items), with a 7 points response scale. The scores range from 40 to 280, with higher values corresponding to worse quality of life [32].

Statistical analysis was performed using GraphPad Prism 5.5. Results are presented as mean±SD and data were analyzed using t-test and One-way ANOVA for comparing groups, and Pearson/Spearman’s coefficient for evaluating correlations. We considered a level of p<0.05 statistically significant.

Results and discussions
We included 22 consecutive patients, 19 women and 3 men, with a mean age of 43.41±11.04 years and a mean disease duration of 9.04±5.89 years. The main characteristics of the study group are presented in table 1.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>SLE Patients</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>43.41±11.04</td>
<td>43.25±10.97</td>
</tr>
<tr>
<td>Sex (women)</td>
<td>19 (86.36%)</td>
<td>20 (95.45%)</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>9.3±4.3</td>
<td>7.8±4.2</td>
</tr>
<tr>
<td>Education level (years)</td>
<td>11.0±4.12</td>
<td>11.2±4.13</td>
</tr>
<tr>
<td>Anti-dsDNA (U/ml)</td>
<td>84.65±1116.7</td>
<td>23.5±11.2</td>
</tr>
<tr>
<td>Anti-Ro (U/ml)</td>
<td>5.68±4.52</td>
<td>3.2±2.1</td>
</tr>
<tr>
<td>ACL IgG (GPL/ml)</td>
<td>21.7±7.42</td>
<td>15.3±5.1</td>
</tr>
<tr>
<td>ACL IgM (GPL/ml)</td>
<td>25.37±19.91</td>
<td>14.5±5.3</td>
</tr>
<tr>
<td>C3 (mg/dl)</td>
<td>83.9±21.98</td>
<td>90.5±14.8</td>
</tr>
<tr>
<td>C4 (mg/dl)</td>
<td>89.4±6.82</td>
<td>90.5±14.8</td>
</tr>
<tr>
<td>Immunosuppressive treatment (% of patients)</td>
<td>12 (54.54%)</td>
<td>10 (45.45%)</td>
</tr>
<tr>
<td>GC (mg/d)</td>
<td>14 (63.63%)</td>
<td>15 (65.22%)</td>
</tr>
<tr>
<td>SLEDAI</td>
<td>7.5±5.68</td>
<td>7.5±5.68</td>
</tr>
<tr>
<td>SLEQol</td>
<td>71.7±10.68</td>
<td>71.7±10.68</td>
</tr>
</tbody>
</table>

The results are presented as mean±standard deviation or percentages (%).

Evaluating the presence of anxiety, we found it present for 14 patients (63.63%) and for 5 of the controls (27.27%), p<0.001; depression was identified in 10 SLE patients (45.45%), significant different compared to controls.
The mean HAM-D score was 8.13 ± 3.35, most of the patients with a value associated to a mild depression; mean HAM-A score was 11.18 ± 6.09, 8 patients with a mild level of anxiety and 5 with a moderate one (fig. 3 a, b).

Assessing quality of life, using SF 36 form, we obtained statistically significant differences between SLE patients and control group, mostly regarding physical functioning (60.21 ± 12.31/ 77.21 ± 13.02; p = 0.01), emotional well-being (67.41 ± 26.71/ 83.80 ± 12.21; p = 0.002) and role limitations due to emotional problems (63.86 ± 34.26/ 83.80 ± 34.92%; p = 0.002). The results are presented in table 2.

Using SLEQol, we obtained a mean score of 71.14 ± 30.68, with limits between 50 and 200 (fig. 3b).

The presence of depression negatively correlated to SF-36 scores, regarding emotional well-being (r = -0.601, p = 0.003), physical functioning (r = -0.497, p = 0.018) and role limitation due to emotional problems (r = -0.412, p = 0.015); similar observations were made for the presence of anxiety: r = -0.489, p = 0.02 for physical functioning, r = -0.477, p = 0.024 for emotional well-being and r = -0.644, p = 0.001 for role limitation due to emotional problems. SLEQol scores moderately correlated both to the presence of anxiety and depression (r = -0.682, p < 0.0001/r = -0.518; p = 0.013).

We found a moderately positive correlation between SLEQol and HAM-D score (r = 0.536; p = 0.029), as for SLEQol and HAM-A (r = 0.551, p = 0.017); for cognitive dysfunction we established as well a moderately positive correlation (r = 0.575, p = 0.041) (table 3).

When evaluating the disease activity in relation to cognitive dysfunction, anxiety and depression, we found a positive correlation between SLEDAI, MoCA, HAM-A and HAM-D (table 3).

SLE is the prototype of connective tissue diseases that can present the complete spectrum of neurologic and psychiatric alterations, cognitive dysfunction, depression and anxiety being more prevalent compared to general population, with an impact on patients’ prognosis and quality of life [1, 2, 16-19].

Our study found a prevalence of cognitive dysfunction of over 50%, most of the patients with a mild degree, frequently involving orientation and attention. The reported percentage varies between 15-80% in different studies, depends on the method of evaluation, heterogeneity of the patients and is more frequent compared to other autoimmune rheumatologic conditions. Several reports, that also used MoCA scale, reported increased percentages, as the report published by Butt et al [33] or El-Shafei et al [34]. Lower percentages, under 10, were published by other authors [35, 36]. A recent metaanalysis, published in 2018, that included 78 reports and over 2400 patients, concluded that cognitive dysfunction prevalence was higher compared to healthy subjects or rheumatoid arthritis [37].

The observation of a positive correlation between disease activity and cognitive dysfunction found in our cohort, was also reported in the Lupus Outcomes Study [38], in the study published by Conti et al [39] or Doman et al [40], whereas other investigations didn’t have similar results [41, 42].

Similar to Calderon et al in 2017 [18], our results showed an impact of cognitive dysfunction on our patients’ quality of life; in a similar manner, a recent study that included 98 NPSLE patients concluded that quality of life is reduced both in physical and mental domains, especially due to emotional problems [17], as well as the results of Hanly et al [43].

Depression and anxiety are commonly diagnosed between SLE patients and the reported prevalence is variable between studies due to different methodology, screening tools and patient selection. Our cohort analysis showed the presence of depression and anxiety in a percentage significantly different compared to health individuals. Consistent to our data, a recent meta-analysis, concerning prevalence levels of depression and anxiety in adult SLE patients, published in 2017, that included 59 studies, reported a prevalence of depression between 2% and 91.7% and of anxiety between 4% and 84% [44], significantly higher compared to general population or other connective tissue diseases [45-51].

<table>
<thead>
<tr>
<th>Table 2</th>
<th>LIFE QUALITY ASSESSED BY SF-36 QUESTIONNAIRE IN SLE PATIENTS AND CONTROLS</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLE mean SD</td>
<td>Controls</td>
</tr>
<tr>
<td>Physical functioning</td>
<td>60.21 ± 12.31</td>
</tr>
<tr>
<td>General health</td>
<td>61.36 ± 16.77</td>
</tr>
<tr>
<td>Energy/fatigue</td>
<td>83.18 ± 7.32</td>
</tr>
<tr>
<td>Pain</td>
<td>84.92 ± 7.95</td>
</tr>
<tr>
<td>Social functioning</td>
<td>84.93 ± 9.71</td>
</tr>
<tr>
<td>Role limitation due to physical health</td>
<td>76.26 ± 23.21</td>
</tr>
<tr>
<td>Role limitation due to emotional problems</td>
<td>63.86 ± 34.26</td>
</tr>
<tr>
<td>Emotional well-being</td>
<td>87.41 ± 26.71</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 3</th>
<th>CORRELATIONS BETWEEN DISEASE ACTIVITY, LIFE QUALITY AND DEPRESSION, ANXIETY AND COGNITIVE DYSFUNCTION SCALE</th>
</tr>
</thead>
<tbody>
<tr>
<td>r</td>
<td>p</td>
</tr>
<tr>
<td>HAM-D</td>
<td>0.411</td>
</tr>
<tr>
<td>HAM-A</td>
<td>0.326</td>
</tr>
</tbody>
</table>

SLEDAI, MoCA, HAM-A and HAM-D (table 3).
The relationship between disease activity, depression and anxiety constituted the aim of several studies, with inconsistent results; in our cohort, we noticed a moderately positive correlation between these variables, in consistency to those previously published by Julian et al [52], Bachen et al. [53] or by Bai et al, in 2016 [54].

Emotional disturbances are proven to negatively impact quality of life and are associated with long term progression of the disease and were extensively studied; a recent report that included a group of 113 SLE patients, concluded that patients with anxiety and/or depression reported lower SF-36 scores compared to that without psychological factors in CNS pathology, Neural Regen Res., 10, nr.9, 2015, p. 1349-1355.

References


Manuscript received: 29.11.2018